Morgan Stanley Downgrades enGene Therapeutics to Underweight

Benzinga Newsdesk Jun 18, 2026 4 months ago

NewsDowngradesAnalyst Ratings

Morgan Stanley analyst Judah Frommer downgrades enGene Therapeutics (NASDAQ:ENGN) from Equal-Weight to Underweight.